Published on 1 Feb 2017
Allergy Therapeutics (LON:AGY) international medical director Dr Matthias
Kramer talks to Proactive about the company taking its Polyvac vaccine
for peanut allergy into a phase I clinical trial after it delivered
positive pre-clinical results.
The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.
The company is developing Polyvac as a short course of injections that is safer and more effective than the current treatments.
No comments:
Post a Comment